Keith Menear

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with <i>In vitro</i> and <i>In vivo</i> Antitumor Activity

Christine M. Chresta, Barry R. Davies, Ian Hickson et al. · Cancer Research · 2009 · 795 citations · Full text

Medicine, Oncology, Pharmacology +13

4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2<i>H</i>-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1

Keith Menear, Claire Adcock, Robert Boulter et al. · Journal of Medicinal Chemistry · 2008 · 586 citations · Full text

Medicine, Oncology, Pharmacology +16

Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion

Sarah E. Golding, Elizabeth Rosenberg, Nicholas C.K. Valerie et al. · Molecular Cancer Therapeutics · 2009 · 389 citations · Full text

Medicine, Cancer Biology, Oncology +14

Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014

Kurt G. Pike, Karine Malagu, Marc Hummersone et al. · Bioorganic & Medicinal Chemistry Letters · 2013 · 206 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Chemosensitization of Cancer Cells by KU-0060648, a Dual Inhibitor of DNA-PK and PI-3K

Joanne M. Munck, Michael A. Batey, Yan Zhao et al. · Molecular Cancer Therapeutics · 2012 · 131 citations · Full text

Medicine, Oncology, Pharmacology +11